Celldex Historical Income Statement

CLDX Stock

USD 26.76 1.38 4.90%

Historical analysis of Celldex Therapeutics income statement accounts such as Interest Expense of 5.8 M, Selling General Administrative of 29.4 M or Total Revenue of 7.6 M can show how well Celldex Therapeutics performed in making a profits. Evaluating Celldex Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Celldex Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Celldex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Celldex Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

About Celldex Income Statement Analysis

Celldex Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Celldex Therapeutics shareholders. The income statement also shows Celldex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Celldex Therapeutics Income Statement Chart

At this time, Celldex Therapeutics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 7.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.5 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Celldex Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Celldex Therapeutics. It is also known as Celldex Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Celldex Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 7.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.5 M in 2024.

	2023	2024 (projected)
Extraordinary Items	17.2M	15.3M
Reconciled Depreciation	2.9M	3.1M

Extraordinary Items Reconciled Depreciation

Celldex Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Cost Of Revenue	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Interest Income	Tax Provision	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		-0.12	0.23	0.43	0.02	0.32	-0.25	-0.32	-0.28	0.19	-0.26	0.12	-0.18	-0.42	0.11	0.33	0.24	-0.12	-0.16	-0.24	0.09	-0.18	-0.13	-0.11
Interest Expense	-0.12		-0.03	0.33	0.15	-0.06	-0.36	0.48	0.48	0.05	-0.38	-0.97	-0.37	-0.02	0.08	-0.04	0.09	-0.43	0.98	0.4	0.32	0.3	-0.2	0.08
Selling General Administrative	0.23	-0.03		0.13	-0.26	0.91	-0.85	-0.84	-0.84	0.66	-0.85	0.13	-0.85	-0.13	0.71	0.89	0.43	-0.8	-0.04	0.28	0.51	0.19	-0.33	-0.36
Total Revenue	0.43	0.33	0.13		-0.01	0.25	-0.31	-0.03	-0.01	0.14	-0.32	-0.3	-0.23	-0.52	0.27	0.2	0.41	-0.13	0.32	0.2	0.21	-0.1	0.09	-0.11
Gross Profit	0.02	0.15	-0.26	-0.01		-0.43	0.29	0.36	0.37	0.47	0.23	-0.38	0.25	-0.32	-0.42	-0.39	-0.01	0.18	0.24	0.29	-0.45	-0.57	0.58	0.87
Other Operating Expenses	0.32	-0.06	0.91	0.25	-0.43		-0.9	-0.89	-0.89	0.53	-0.89	0.19	-0.88	-0.13	0.81	0.99	0.41	-0.81	-0.07	0.18	0.39	0.13	-0.31	-0.58
Operating Income	-0.25	-0.36	-0.85	-0.31	0.29	-0.9		0.65	0.64	-0.58	1.0	0.23	0.98	0.12	-0.77	-0.91	-0.46	0.95	-0.34	-0.37	-0.51	-0.25	0.38	0.43
Ebit	-0.32	0.48	-0.84	-0.03	0.36	-0.89	0.65		1.0	-0.54	0.63	-0.56	0.63	0.12	-0.67	-0.89	-0.37	0.55	0.47	-0.05	-0.19	0.05	0.15	0.44
Ebitda	-0.28	0.48	-0.84	-0.01	0.37	-0.89	0.64	1.0		-0.54	0.63	-0.57	0.63	0.1	-0.67	-0.88	-0.37	0.55	0.47	-0.06	-0.19	0.04	0.15	0.44
Total Operating Expenses	0.19	0.05	0.66	0.14	0.47	0.53	-0.58	-0.54	-0.54		-0.62	-0.11	-0.59	-0.4	0.41	0.57	0.5	-0.57	0.11	0.6	0.06	-0.27	0.21	0.32
Income Before Tax	-0.26	-0.38	-0.85	-0.32	0.23	-0.89	1.0	0.63	0.63	-0.62		0.26	0.99	0.13	-0.74	-0.89	-0.48	0.96	-0.37	-0.38	-0.48	-0.22	0.35	0.38
Total Other Income Expense Net	0.12	-0.97	0.13	-0.3	-0.38	0.19	0.23	-0.56	-0.57	-0.11	0.26		0.24	0.1	0.06	0.17	-0.06	0.32	-0.97	-0.42	-0.17	-0.14	0.03	-0.29
Net Income	-0.18	-0.37	-0.85	-0.23	0.25	-0.88	0.98	0.63	0.63	-0.59	0.99	0.24		-0.02	-0.69	-0.88	-0.47	0.97	-0.36	-0.31	-0.46	-0.27	0.41	0.39
Income Tax Expense	-0.42	-0.02	-0.13	-0.52	-0.32	-0.13	0.12	0.12	0.1	-0.4	0.13	0.1	-0.02		-0.37	-0.17	-0.07	0.02	-0.05	-0.58	-0.04	0.5	-0.53	-0.21
Cost Of Revenue	0.11	0.08	0.71	0.27	-0.42	0.81	-0.77	-0.67	-0.67	0.41	-0.74	0.06	-0.69	-0.37		0.83	0.2	-0.71	0.1	0.5	0.33	0.02	-0.05	-0.5
Research Development	0.33	-0.04	0.89	0.2	-0.39	0.99	-0.91	-0.89	-0.88	0.57	-0.89	0.17	-0.88	-0.17	0.83		0.37	-0.83	-0.05	0.24	0.37	0.09	-0.28	-0.55
Selling And Marketing Expenses	0.24	0.09	0.43	0.41	-0.01	0.41	-0.46	-0.37	-0.37	0.5	-0.48	-0.06	-0.47	-0.07	0.2	0.37		-0.26	0.08	0.26	0.28	0.17	-0.14	0.18
Net Income From Continuing Ops	-0.12	-0.43	-0.8	-0.13	0.18	-0.81	0.95	0.55	0.55	-0.57	0.96	0.32	0.97	0.02	-0.71	-0.83	-0.26		-0.43	-0.35	-0.4	-0.19	0.33	0.37
Non Recurring	-0.16	0.98	-0.04	0.32	0.24	-0.07	-0.34	0.47	0.47	0.11	-0.37	-0.97	-0.36	-0.05	0.1	-0.05	0.08	-0.43		0.45	0.22	0.19	-0.09	0.16
Non Operating Income Net Other	-0.24	0.4	0.28	0.2	0.29	0.18	-0.37	-0.05	-0.06	0.6	-0.38	-0.42	-0.31	-0.58	0.5	0.24	0.26	-0.35	0.45		0.26	-0.09	0.34	0.32
Interest Income	0.09	0.32	0.51	0.21	-0.45	0.39	-0.51	-0.19	-0.19	0.06	-0.48	-0.17	-0.46	-0.04	0.33	0.37	0.28	-0.4	0.22	0.26		0.76	-0.7	-0.36
Tax Provision	-0.18	0.3	0.19	-0.1	-0.57	0.13	-0.25	0.05	0.04	-0.27	-0.22	-0.14	-0.27	0.5	0.02	0.09	0.17	-0.19	0.19	-0.09	0.76		-0.89	-0.41
Reconciled Depreciation	-0.13	-0.2	-0.33	0.09	0.58	-0.31	0.38	0.15	0.15	0.21	0.35	0.03	0.41	-0.53	-0.05	-0.28	-0.14	0.33	-0.09	0.34	-0.7	-0.89		0.53
Extraordinary Items	-0.11	0.08	-0.36	-0.11	0.87	-0.58	0.43	0.44	0.44	0.32	0.38	-0.29	0.39	-0.21	-0.5	-0.55	0.18	0.37	0.16	0.32	-0.36	-0.41	0.53

Click cells to compare fundamentals

Celldex Therapeutics Account Relationship Matchups

Celldex Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	(3.1M)	2M	3.1M	1.4M	3.0M	1.5M
Selling General Administrative	15.4M	14.5M	20.5M	27.2M	30.9M	29.4M
Total Revenue	3.6M	7.4M	4.7M	2.4M	6.9M	7.6M
Gross Profit	(39.1M)	(35.1M)	1.6M	957K	(111.1M)	(105.6M)
Other Operating Expenses	58.1M	57.0M	73.8M	109.5M	161.4M	169.5M
Operating Income	(55.0M)	(63.4M)	(71.2M)	(115.2M)	(154.5M)	(146.8M)
Ebit	(55.0M)	(47.6M)	(69.1M)	(105.6M)	(142.0M)	(134.9M)
Ebitda	(58.2M)	(45.6M)	(66.1M)	(104.2M)	(139.0M)	(132.1M)
Total Operating Expenses	58.1M	57.0M	73.8M	109.5M	43.4M	45.3M
Income Before Tax	(50.9M)	(60.9M)	(70.7M)	(112.3M)	(141.4M)	(134.4M)
Total Other Income Expense Net	4.2M	2.4M	505K	2.9M	13.1M	13.8M
Net Income	(50.4M)	(59.8M)	(70.5M)	(122.8M)	(141.4M)	(134.4M)
Income Tax Expense	(506K)	(1.2M)	(227K)	10.5M	2.8M	1.6M
Cost Of Revenue	42.7M	42.5M	3.1M	1.4M	118.0M	123.9M
Research Development	42.7M	42.5M	53.3M	82.3M	118.0M	123.9M
Net Income From Continuing Ops	(50.9M)	(59.8M)	(70.5M)	(112.3M)	(124.6M)	(130.8M)
Non Recurring	109.7M	1.8M	18M	3.5M	4.0M	3.8M
Non Operating Income Net Other	4.5M	4.2M	2.4M	505K	580.8K	551.7K
Net Income Applicable To Common Shares	(50.9M)	(59.8M)	(70.5M)	(112.3M)	(101.1M)	(106.1M)
Reconciled Depreciation	4.9M	3.9M	3.1M	2.9M	2.9M	3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Celldex Historical Income Statement

About Celldex Income Statement Analysis

Celldex Therapeutics Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Celldex Therapeutics income statement Correlations

Celldex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Celldex Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Celldex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Research Development	+ 0.99	Other Operating Expenses
Net Income	+ 0.99	Income Before Tax
Non Recurring	+ 0.98	Interest Expense
Net Income	+ 0.98	Operating Income

Non Recurring	- 0.97	Total Other Income Expense Net
Total Other Income Expense Net	- 0.97	Interest Expense
Research Development	- 0.91	Operating Income
Operating Income	- 0.9	Other Operating Expenses
Reconciled Depreciation	- 0.89	Tax Provision
Research Development	- 0.89	Income Before Tax